The analysis of antimicrobial resistance for bacteria among northern, central and southern Anhui Province in 2019

HE Ling-ling; LIU Yan-yan; LI Jia-bin

doi:10.16462/j.cnki.zhjbkz.2021.07.022

Volume 25 Issue 7

Aug. 2021

Turn off MathJax

Article Contents

Article Navigation > CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION > 2021 > 25(7): 859-863

HE Ling-ling, LIU Yan-yan, LI Jia-bin. The analysis of antimicrobial resistance for bacteria among northern, central and southern Anhui Province in 2019[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2021, 25(7): 859-863. doi: 10.16462/j.cnki.zhjbkz.2021.07.022

Citation:

HE Ling-ling, LIU Yan-yan, LI Jia-bin. The analysis of antimicrobial resistance for bacteria among northern, central and southern Anhui Province in 2019[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2021, 25(7): 859-863. doi: 10.16462/j.cnki.zhjbkz.2021.07.022

Citation:

PDF( 832 KB)

The analysis of antimicrobial resistance for bacteria among northern, central and southern Anhui Province in 2019

doi: 10.16462/j.cnki.zhjbkz.2021.07.022

HE Ling-ling¹,
LIU Yan-yan^{1, 2},
LI Jia-bin^{1, 2
,
,}

1.
Department of Infectious Diseases, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China
2.
Anhui Center for Surveillance of Bacterial Resistance, Institute of Bacterial Resistance, Anhui Medical University, Hefei 230022, China

Funds:

National Natural Science Foundation of China 81973983

National Science and Technology Major Project 2017ZX10204401

Borrowing and Transferring Subsidy Project in 2019, Hefei J2019Y04

More Information

Corresponding author: LI Jia-bin, E-mail: lijiabin@ahmu.edu.cn
Received Date: 2021-01-03
Rev Recd Date: 2021-03-02

Available Online: 2021-08-13

Publish Date: 2021-07-10

Abstract

Abstract

Objective To analyze the differences of clinical distribution and antimicrobial resistance of pathogenic bacteria among northern central and southern Anhui in 2019, and to provide a rational reference for clinicians in different regions. Methods The strains were collected from 38 hospitals of Anhui Center for Surveillance of Bacterial Resistance in 2019. Strains divided were according to northern, central and southern Anhui by region. WHONET 5.6 software and SPSS17.0 software were used for data analysis. Results The percentage of Methicillin-resistant Staphylococcus aureus in northern Anhui was higher than in central and southern Anhui. The resistance rates of cefoperazone/sulbactam for Pseudomonas aeruginosa and Acinetobacter baumannii were 20.8% and 60.4%, respectively. The percentage of Carbapenem-resistant Klebsiella pneumoniae in central Anhui was higher than those in northern Anhui and southern Anhui. The resistance rate of cephalothin for Klebsiella pneumoniae was > 40.0%, and the resistance rates of imipenem and meropenem were > 20.0%. The resistance rates of aminoglycosides and quinolones for Methicillin-resistant Staphylococcus in southern Anhui were higher than those in northern Anhui. Conclusions There are significant diffenences in bacterial resistance of different regions in Anhui Province. It is necessary to use antimicrobialagents rationally according to the resistance of bacteria in the local region.
- Bacterial resistance,
- Pathogenic bacteria,
- Antibacterial agents,
- Durg resistance

FullText(HTML)

References(10)

References

[1]	石荔, 杨玉妹, 汤瑾, 等. 2017年度西藏与上海两家三甲医院细菌与抗菌药物耐药分析[J]. 中华医院感染学杂志, 2020, 30(12): 1816-1821. DOI: 10.11816/cn.ni.2020-190738. Shi L, Yang YM, Tang J, et al. Analysis of the bacterial and antibacteril drug resistance spectrum of the top three hospitals in Tibet and Shanghaiin 2017[J]. Chin J Nosocomiol, 2020, 30(12): 1816-1821. DOI: 10.11816/cn.ni.2020-190738.
[2]	胡付品, 郭燕, 朱德妹, 等. 2019年CHINET三级医院细菌耐药监测[J]. 中国感染与化疗杂志, 2020, 20(3): 233-243. DOI: 10.16718/j.1009-7708.2020.03.001. Hu FP, Guo Y, Zhu DM, et al. CHINET surveillance of bacterial resistance across tertiary hospitals in 2019[J]. Chin J Infect Chemother, 2020, 20(3): 233-243. DOI: 10.16718/j.1009-7708.2020.03.001.
[3]	VJung N, Rieg S. Essentials in the management of S. aureus bloodstream infection[J]. Infection, 2018, 46(4): 441-442. DOI: 10.1007/s15010-018-1130-8.
[4]	吕贞燕, 耿先龙, 王春新. 儿童患者耐甲西林金黄色葡萄球菌的耐药特征及分子流行病学分型[J]. 临床检验杂志, 2018, 36(10): 792-794. DOI: 10.13602/j.cnki.jcls.2018.10.18. Lv ZY, Geng XL, Wang CX. Drug resistance characteristics and moleculr epidemiology of Methicillin-resistant Staphylococcus aureus in children[J]. Chin J Clin Lab Sci, 2018, 36(10): 792-794. DOI: 10.13602/j.cnki.jcls.2018.10.18.
[5]	胡付品, 郭燕, 朱德妹, 等. 2017年CHINET中国细菌耐药性监测[J]. 中国感染与化疗杂志, 2018, 18(3): 241-251. DOI: 10.16178/j.1009-7708.2018.03.001. Hu FP, Guo Y, Zhu DM, et al. Antimicrobial resistance profile of clinical isolates in hospitals across China: report from the CHINET surveillance program, 2017[J]. Chin J Infect Chemother, 2018, 18(3): 241-251. DOI: 10.16178/j.1009-7708.2018.03.001.
[6]	Li SG, Sun SJ, Yang CT, et al. The Changing pattern of population structure of staphylococcus aureus from bacteremia in China from 2013 to 2016: ST239-030-MRSA replaced by ST59-t437[J]. Front Microbiol, 2018, 9: 332. DOI: 10.3389/fmicb.2018.00332.
[7]	Shariati A, Dadashi M, Moghadam MT, et al. Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis[J]. Sci Rep, 2020, 10(1): 12689. DOI: 10.1038/s41598-020-69058-z.
[8]	喻华, 徐雪松, 李敏, 等. 肠杆菌目细菌碳青霉烯酶的实验室检测和临床报告规范专家共识[J]. 中国感染与化疗杂志, 2020, 20(6): 671-680. DOI: 10.16178/j.1009-7708.2020.06.015. Yu H, Xu XH, Li M, et al. Consensus statement on laboratory detection and clinical report of carbapenemases among Enterobacterales[J]. Chin J Infect Chemother, 2020, 20(6): 671-680. DOI: 10.16178/j.1009-7708.2020.06.015.
[9]	Durante-Mangoni E, Andini R, Zampino R. Management of carbapenem-resistant Enterobacteriaceae infections[J]. Clin Microbiol Infect, 2019, 25(8): 943-950. DOI: 10:1016/j.cmi.2019.04.013.
[10]	马进宝, 马婷婷, 任斐. 阿米卡星在耐多药结核病治疗中引起耳毒性研究进展[J]. 中国热带医学, 2020(3): 288-290. DOI: 10.13604/j.cnki.46-1064/r.2020.03.21. Ma JB, Ma TT, Ren F. Progress of ototoxicity induced by amikacin in the treatment of multidrug-resistant tuberculosis[J]. China Tropical Medicine, 2020, 20(3): 288-290. DOI: 10.13604/j.cnki.46-1064/r.2020.03.21.